The Prevalence, Types, and Risk Factors of Chronic Heart Failure (CHF) in End-Stage Kidney Disease Patients with Symptomatic CHF Heart Failure in End-Stage Kidney Disease
Article Sidebar
Main Article Content
Abstract
OBJECTIVE: The objective of this study was to investigate the prevalence, types, and risk factors of chronic heart failure in Thai patients with end-stage kidney disease (ESKD).
METHODS: In this retrospective study, the authors examined patients with clinical heart failure in ESKD at Pranangklao Hospital between January 2021 and May 2022.
RESULTS: The study enrolled a total of 128 patients, with an average age of 58.82 ± 14.44 years, of which 56.30% were male. The average body surface area was 883.48 ± 398.41 m2. The majority of patients received hemodialysis (65.60%). Hypertension and dyslipidemia were the most common comorbidities, and folic acid and statins were the most commonly prescribed medications. There were no statistically significant differences in left ventricular ejection fraction between patients receiving hemodialysis versus peritoneal dialysis. The study found that among the 3 different heart failure groups by left ventricular ejection fraction (LVEF) (LVEF 40%, 41-49%,
50%), the LVEF was 10 (7.81%), 7 (5.46%), and 111 (86.73%), respectively. Similarly, the diastolic function grades (grade I, II, III) were 62 (55.86%), 46 (41.44%), and 3 (2.70%), respectively. Patients with coronary artery disease had a significantly lower left ventricular ejection fraction.
CONCLUSION: Diastolic dysfunction and grade I diastolic dysfunction are common in Thai patients with ESKD.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011) 2022;12(1):7-11.
Centers for Disease Control and Prevention. National chronic kidney disease fact sheet: general information and national estimates on chronic kidney disease in the United States, 2014. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2014.
Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant 2018;33(suppl 3):iii28-34.
Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J, et al. US renal data system 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2016;67(3 Suppl 1):S1-305.
Rangaswami J, Mathew RO, Parasuraman R, Tantisattamo E, Lubetzky M, Rao S, et al. Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. Nephrol Dial Transplant 2019;34(5):760-73.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599-726.
Tsilonis K, Sarafidis PA, Kamperidis V, Loutradis C, Georgianos PI, Imprialos K, et al. Echocardiographic parameters during long and short interdialytic intervals in hemodialysis patients. Am J Kidney Dis 2016;68(5):772-81.
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Hear J-Cardiovasc Imaging 2016;17(12):1321–60.
Elkaialy AA, Walid MS, Thabet SS, Gharieb MA. Prevalence of left ventricular diastolic dysfunction by tissue doppler imaging in patients with end stage renal disease undergoing regular dialysis with preserved systolic function. Int J Med 2021;114 Suppl 1.
Han JH, Han JS, Kim EJ, Doh FM, Koo HM, Kim CH, et al. Diastolic dysfunction is an independent predictor of cardiovascular events in incident dialysis patients with preserved systolic function. PLoS One 2015;10(3):e0118694.
Lekawanvijit S. Cardiotoxicity of uremic toxins: a driver of cardiorenal syndrome. Toxins (Basel) 2018;10(9):352.
Edwards NC, Price AM, Steeds RP, Ferro CJ, Townend JN. Management of heart failure in patients with kidney disease-updates from the 2021 ESC guidelines. Nephrol Dial Transplant 2023;38(8):1798-806.